Disease · MONDO_0005311

atherosclerosis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. atherosclerosis. Diseases, record MONDO_0005311. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005311

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: atherosclerosis; Open Targets
Open Targets ID: MONDO_0005311; Open Targets
Other names: Atherogenesis, Atheroscleroses, atherosclerosis of artery; Open Targets
Disease Ontology: DOID:1936; Disease Ontology
MeSH: D050197; MeSH
NCI Thesaurus: C35768; NCI Thesaurus
Highest stage of its drugs: Approval, for 7 of its 84 drugs, from DailyMed and FDA; Open Targets

Drugs84

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
EZETIMIBE	CHEMBL1138	Small molecule	Approval	DailyMed	8	7	7	Drugs and targets
NIACIN	CHEMBL573	Small molecule	Approval	DailyMed	7	6	6	Drugs and targets
LOVASTATIN	CHEMBL503	Small molecule	Approval	DailyMed	4	2	2	Drugs and targets
INCLISIRAN SODIUM	CHEMBL5095052	Oligonucleotide	Approval	FDA	2	1	1	Drugs and targets
BEMPEDOIC ACID	CHEMBL3545313	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
PRAVASTATIN SODIUM	CHEMBL690	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
ROSUVASTATIN CALCIUM	CHEMBL1744447	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
ATORVASTATIN	CHEMBL1487	Small molecule	Phase 3	ClinicalTrials.gov	12	12	12	Drugs and targets
ROSUVASTATIN	CHEMBL1496	Small molecule	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
ROSIGLITAZONE	CHEMBL121	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets

1 to 10 of 84

See all 84 drugs

Targets130

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
HMGCR	3-hydroxy-3-methylglutaryl-coenzyme A reductase	6	HMG-CoA reductase inhibitor	Approval	https://conductscience.org/library/genes/3156	Drugs and targets
PPARG	Peroxisome proliferator-activated receptor gamma	4	Peroxisome proliferator-activated receptor gamma agonist	Phase 3	https://conductscience.org/library/genes/5468	Drugs and targets
AGTR1	Type-1 angiotensin II receptor	3	Type-1 angiotensin II receptor agonist; Type-1 angiotensin II receptor antagonist	Phase 3	https://conductscience.org/library/genes/185	Drugs and targets
CSF3R	Granulocyte colony-stimulating factor receptor	3	Granulocyte colony stimulating factor receptor agonist	Phase 1	https://conductscience.org/library/genes/1441	Drugs and targets
EPOR	Erythropoietin receptor	3	Erythropoietin receptor agonist	Unknown	https://conductscience.org/library/genes/2057	Drugs and targets
PCSK9	PCSK9 mRNA	3	PCSK9 mRNA RNAi inhibitor; PCSK9 mRNA rnai inhibitor; Subtilisin/kexin type 9 inhibitor	Approval	https://conductscience.org/library/genes/255738	Drugs and targets
ADRB1	Adrenergic receptor	2	Adrenergic receptor agonist; Beta-1 adrenergic receptor antagonist	Phase 2	https://conductscience.org/library/genes/153	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	2	FK506-binding protein 1A inhibitor	Phase 3	https://conductscience.org/library/genes/2280	Drugs and targets
IL1B	Interleukin-1 beta	2	Interleukin-1 beta inhibitor	Phase 2	https://conductscience.org/library/genes/3553	Drugs and targets
MAPK14	Mitogen-activated protein kinase 14	2	MAP kinase p38 alpha inhibitor	Phase 2	https://conductscience.org/library/genes/1432	Drugs and targets

1 to 10 of 130

See all 130 targets

Trials90

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT05142722	Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies	Phase 3	2,530	2025-09-19	Dyslipidemias, High Cholesterol, Hypercholesterolemia, Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease	OBICETRAPIB	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT04807400	Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support	Phase 3	892	2024-03-25	Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease Risk Equivelents, Elevated Low Density Lipoprotein Cholesterol	INCLISIRAN, INCLISIRAN SODIUM	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT00116831	Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes	Phase 3	672	2010-03-31	Atherosclerosis	GLIPIZIDE, ROSIGLITAZONE MALEATE	Its record names the disease	ClinicalTrials.gov
NCT00114517	ELITE: Early Versus Late Intervention Trial With Estradiol	Phase 2	643	2017-06-08	Atherosclerosis	ESTRADIOL	Its record names the disease	ClinicalTrials.gov
NCT02546323	A phase3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects With Subclinical Atherosclerosis	Phase 3	543	2019-12-11	Atherosclerosis	ROSUVASTATIN	Its record names the disease	ClinicalTrials.gov
NCT01483560	REducing With MetfOrmin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL)	Phase 3	493	2019-06-03	Diabetes Mellitus, Type 1	METFORMIN	Its record names the disease	ClinicalTrials.gov
NCT00455403	Atheroma Reduction With Chloroquine in Patients With the Metabolic Syndrome (ARCH-MS)	Not applicable	357	2021-06-25	Metabolic Syndrome X, Overweight, Hypertension, Dyslipidemias, Prediabetic State	CHLOROQUINE	Its record names the disease	ClinicalTrials.gov
NCT03926117	Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition	Phase 2	264	2023-08-09	Chronic Kidney Diseases, Inflammation	ZILTIVEKIMAB	Its record names the disease	ClinicalTrials.gov
NCT00358826	Study Effect of VIA-2291 on Vascular Inflammation	Phase 2	191	2012-07-23	Coronary Artery Disease	ATRELEUTON	Its record names the disease	ClinicalTrials.gov
NCT00995930	Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients	Phase 2	189	2015-03-06	Diabetes Mellitus, Type 2, Atherosclerosis, Prediabetic State	CANAKINUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 90

See all 90 trials

Comparisons in its trials30

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Obicetrapib 10mg vs Placebo: deaths from any cause	19 of 1,685	12 of 843	2,528	NCT05142722	Trial comparisons
Obicetrapib 10mg vs Placebo: serious adverse events	211 of 1,685	117 of 843	2,528	NCT05142722	Trial comparisons
Glipizide (GLP) 5 mg vs Rosiglitazone (RSG) 4 mg: Number of Participants With the Indicated Treatment Emergent Major Cardiovascular Events (MACE) for All-cause Death, Non-fatal MI, Non-fatal Stroke, Coronary Revascularization, or Hospitalization for Recurrent Myocardial Ischemia (MACE Composite 1)	38 of 337	39 of 331	668	NCT00116831	Trial comparisons
Glipizide (GLP) 5 mg vs Rosiglitazone (RSG) 4 mg: Number of Participants With the Indicated Treatment Emergent Major Cardiovascular Events (MACE) for Cardiovascular Death, Nonfatal MI, or Nonfatal Stroke (MACE Composite 2)	10 of 337	14 of 331	668	NCT00116831	Trial comparisons
Glipizide (GLP) 5 mg vs Rosiglitazone (RSG) 4 mg: serious adverse events	71 of 337	71 of 331	668	NCT00116831	Trial comparisons
17B-estradiol vs Placebo: deaths from any cause	1 of 323	1 of 320	643	NCT00114517	Trial comparisons
17B-estradiol vs Placebo: serious adverse events	43 of 323	45 of 320	643	NCT00114517	Trial comparisons
Inclisiran vs Inclisiran + BS: Number of Participants Interviewed for CFIR Analysis.	28 of 297	28 of 297	594	NCT04807400	Trial comparisons
Rosuvastatin 20 mg vs Placebo: deaths from any cause	0 of 272	1 of 268	540	NCT02546323	Trial comparisons
Rosuvastatin 20 mg vs Placebo: serious adverse events	38 of 272	34 of 268	540	NCT02546323	Trial comparisons

1 to 10 of 30

See all 30 comparisons in its trials

Papers from its trials76

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40337982	RESULT	1	PubMed
35212585	RESULT	1	PubMed
33303068	RESULT	1	PubMed
31504439	RESULT	1	PubMed
29301785	RESULT	1	PubMed
27421538	RESULT	1	PubMed
27028912	RESULT	1	PubMed
26630643	RESULT	1	PubMed
26606676	RESULT	1	PubMed
26429851	RESULT	1	PubMed

1 to 10 of 76

See all 76 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005311

GET https://conductscience.org/api/diseases/v1/MONDO_0005311/drugs?page=2

API reference For AI assistants